95% of serum and 90% of CSF specimens tested positive for anti-LGI1 antibodies.
40% showed normal cranial MRI results; 55% had standard CSF protein levels.
80% achieved favorable functional recovery at 12 months.
Interpretation:
Older age, prolonged diagnostic delays, and elevated antibody titers are significant indicators of unfavorable outcomes in anti-LGI1 encephalitis, highlighting the need for timely intervention.
Limitations:
Small sample size of 20 individuals may limit generalizability.
Retrospective nature may introduce bias.
Potential for incomplete data due to reliance on existing clinical records.
Conclusion:
Prompt antibody testing in both serum and CSF is essential to reduce diagnostic delays and improve long-term outcomes in anti-LGI1 encephalitis, emphasizing the need for immediate clinical action.
Guidance addresses office readiness, recommended equipment and medications, and team communication processes for infrequent but high-acuity emergencies.
